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Liver summary  IHPBA 2008
Colorectal liver metastases have been the major focus
of interest throughout the meeting. After surgery alone,
10 years actual and DF survival are 16 and 14%
(FP12.02). However, approximately one-third of the
10 years DF survivors had undergone repeat surgery
and the same proportion of five years DF survivors
developed recurrence. The latter undermines the need
for continued follow-up which has been suggested by
another group to be a three monthly surveillance
during the first two years (FP12.03). Besides classical
risk factors of recurrence, the lack of normalisation of
CEA level within six weeks of surgery has been
identified (FP12.04). Response to preoperative che-
motherapy is however emerging as more powerful than
the classical Memorial Sloan-Kettering Cancer Center
(MSKCC) score (FP31.03) and although still a rare
event, complete response is increasingly reported
(FP27.07, FP35.01, FP35.03, FP35.04). There re-
mains however much controversies on the potential
side effects of neoadjuvant chemotherapy. In itself,
neither the classical (FP27.02) nor the new antiangio-
genic agents (FP31.01) affect the perioperative out-
come. However, severe sinusoidal obstructive
syndrome may increase the risk of postoperative
insufficiency (PL1.01, FP27.04). Attempts to further
assess these chemotherapy associated injuries have
included electron microscopy (FP31.05), measure-
ment of portal pressure (FP27.05), Aspartate amino
transferase (AST)/platelets ratio (FP27.04) and MRI
(PP11.04). Although portal vein embolisation (PVE)
 or portal vein ligation which is as effective (AP5.04)
 may be used to increase respectability, there is some
evidence that it may increase cancer cell proliferation
(AP3.02).
HepatoCellular Carcinoma (HCC) continues to be
a major focus of interest in both the East and the West
including northern European countries were the
prevalence of this cancer was traditionally low. The
efficacy of RF is confirmed in the long term with five
years survival of 43% that reaches 59% for tumours
up to 3 cm (AP5.02). On the other hand, there is an
increasing trend to consider resection (besides trans-
plantation) in some patients fulfilling the Milan
criteria. There have been attempts to improve,
through non-invasive means, staging of the fibrosis
grade through the AST/platelets ratio (FP13.05), liver
function through branched chain amino acids/Thyr-
osine ratio (FP13.06) and microscopic portal vein
invasion through the measurement of the perfusion
defect area during CT arterial portography
(FP13.04). It is still unclear whether anatomical
resection is superior (PP1.09) or equal to (FP2.08)
non-anatomical resection. HCC located in segment 1,
a troublesome location, have a prognosis comparable
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to those in segment 4 (PP1.07) and can be success-
fully treated by RF (FP22.05).
Clamping of the hepatic pedicle did not receive
much attention but the trend is to use it more and more
selectively as a meta-analysis failed to demonstrate any
benefit in perioperative outcome (PP57.09). The
Hong Kong group, who first reported through a
randomized controlled trial (RCT) the benefit of the
Pringle manoeuvre 10 years ago, currently use it in less
than 3% of their patients (FP25.06). Microdialysis
catheters placed in the liver have been used to monitor
the biochemical consequence of ischemia/reperfusion
(PP4.08) and may help in the future to tailor the
duration of clamping. Several groups have presented
their experience with laparoscopic liver resections.
The trend is to extend this approach to malignancies
that now account for up to 80% of the indications in
some centres (FP37.01 and PP2.01). Eighteen right
hepatectomies have also been reported, without con-
version (FP37.07). Laparoscopic right portal vein
ligation is also feasible (FP37.04) which may prove
useful at a time when laparoscopic colorectal resections
also develop.
Rehabilitation is obviously becoming a focus of
interest. Fast track liver major surgery is starting to
develop (AP3.06) and the only RCT on liver surgery
presented during the meeting was devoted to pain
control through wound instillation of Ropivacaine
(FP25.08). This is probably not fortuitous, as
the sample size of a hypothetical RCT aiming to
show a reduction in mortality or morbidity is so high
(5000) that it is hardly feasible (PP33.03).
Oliver Farges
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Transplantation summary  IHPBA 2008
Liver transplantation has become an integral part of
the practice of HPB surgery, and the most current
topics in the field were very well covered at the 2008
IHPBA meeting. These topics included living donor
liver transplant (LDLT), methods to expand the
deceased donor (DD) pool, recurrence of disease
(HCC, Hep C, Hep B), and morbidity associated
with long-term immunosuppression.
Worldwide, LDLT is a rapidly growing procedure,
with likely10,000 such procedures performed to
date. Donor morbidity and mortality associated with
the procedure remain a significant concern. By some
reports, there have been 28 donor deaths and an
additional four donors receiving liver transplants
themselves [1]. The problem, however, has been
that poor reporting has made both the number of
such transplants, and the number of donor deaths
difficult to quantify accurately. Based on the results
summarized from a recent worldwide forum, the
estimated risk of donor mortality is 0.5%, and
morbidity 35%. Individual center reports suggest
that 95% of donors returned to predonation level of
quality of life within six months, but long-term follow-
up is necessary. Recipient results with LDLT have
improved, and are now equivalent to DD results [2].
According to North American data, technical com-
plications, especially biliary complications, remain
high but significant surgical advances have been
made [3]. The Asan Medical Center in South Korea
presented an over 1500 LDLTs, 286 of them per-
formed in 2007. Multiple graft types were utilized
including right lobe (with and without middle hepatic
vein [MHV]), left lobe, dual left lobe, and combined
right and left lobes. Keys to achieving technical
success were adequate graft volume, secure biliary
anastomosis, sufficient inflow, and good outflow [4].
Survival rates of 80% at five years were reported
from the center. Several controversies were addressed
in different sessions including right vs. left lobe,
routine inclusion of MHV, and technique for biliary
reconstruction.
Methods to increase the DD pool were discussed;
including donation after cardiac death (DCD) and
split-liver transplantation (SLT). With DCD donors,
biliary complications and poor survival rates remain a
concern. But with careful donor selection (donor age
B45, WITB30 min and CITB10 h) combined with
careful recipient selection (MELD 1530), centers
such as Leeds, UK have reported good results.
Similarly, SLTs represent another method to expand
the donor pool successfully, as illustrated by results
from the European Split database with 2107 SLTs
performed between 1997 and 2004. The results have
improved, but ongoing issues including in situ vs. ex
situ splitting, appropriate center and recipient selec-
tion, allocation, and adult/adult utilization remain.
Hepatocellular carcinoma (HCC) represents an
increasingly common indication for transplant, and
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data was presented on the ideal candidate. While the
Milan criteria provides good results, is it too restric-
tive? Data on expanded indications, such as the
UCSF criteria, show that equivalent results can be
obtained with low rates of recurrence. Recurrence of
Hep B after transplant seems to be well controlled
with current antiviral regimens, but Hep C recurrence
remains a major problem with poor options available
at present.
With the success of liver transplantation, numerous
new centers have been established in areas such as
Africa, India, and China. An interesting session
discussed some of the issues relevant to these pro-
grams, including establishment of infrastructure, cost
issues, development of appropriate teams and exper-
tise, and establishment of DD protocols. It was clear
that the upcoming few years would see a dramatic
increase in activity at these centers.
Pancreas transplantation, both whole organ and
islet cell, was covered briefly. Long-term results
remain significantly superior with whole organ vs.
islet cell transplantation. Surgical complications re-
main higher after whole organ transplant, but have
improved with surgical refinements and better donor
selection.
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Biliary summary  IHPBA 2008
The Biliary session began on 28th February with a
symposium on hilar cholangiocarcinoma. First up,
was a talk by Prof. Jarnagin of MSKCC on preopera-
tive staging of hilar cholangiocarcinoma. He stressed
that MRCP, Duplex scanning to visualise blood
vessels and FDG-PET were most useful preoperative
imaging modalities. Staging laparotomy may help
identify a subset of patients with advanced disease.
3D imaging is promising. Despite all these, local
resectability may be underestimated.
Prof. Hideki Nishio talked about the Nagoya
strategy in surgical treatment of hilar cholangiocarci-
noma. He showed that over time major resection
showed shorter operating time, less blood loss, lesser
operative mortality and improved long-term survival.
This was attributed to portal vein embolisation, bile
replacement, use of synbiotics and autologus transfu-
sion.
Subsequently, Prof. Peter Neuhaus discussed ex-
tended lymphadenectomy and portal vein excision in
hilar cholangiocarcinoma. He stressed upon preopera-
tive portal vein embolisation, biliary drainage, ex-
tended resection and routine portal vein resection.
This led to 10% mortality but gave 60% five-year
survival. However, the MSKCC group objected to
routine portal vein excision.
Lastly, Prof. Nakeeb Attila discussed the role of
adjuvant therapy in hilar cholangiocarcinoma. The
addition of inter and postoperative radiotherapy has
shown to improve survival in some studies. Todor-
oki showed this to improve survival from 13.5 to
39.2%. However, others did not show benefit of
radiotherapy. Chemotherapy is still under evalua-
tion.
A symposium on choledochal cysts was conducted.
First, Prof. Adarsh Chaudhary spoke on complica-
tions of choledochal cyst. He classified them as septic
and non-septic. Portal hypertension was a major
factor in morbidity and mortality of choledochal cyst
surgery.
Prof. Garden discussed management of Caroli’s
disease. In the rare localised type resection may be
appropriate. Obstructing stones may need removal
and hepaticojejunostomy to be done. Transplantation
is an option in case of liver failure.
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A wider debate on open versus laparoscopic hepa-
ticojejunostomy seemed to indicate that as yet open
hepaticojejunostomy is the standard. Laparoscopic
hepaticojejunostomy needs advanced skills and may
be appropriate for large ducts.
A debate on preoperative biliary drainage in type III
Hilar Cholangiocarcinoma had Prof. Nimura sup-
porting it. He stressed that, it had therapeutic value
with lesser morbidity and better survival. It was also of
diagnostic value in changing the classification in some
patients. However, Bill Janargin showed that MSKCC
data showed improved results without routine pre-
operative biliary drainage. Clearly, cholangitis entails
drainage but in other patients it is controversial.
Prof. Tadahiro Takada presented the international
consensus guidelines on cholangitis and cholecystitis.
The methodology of arriving at the guidelines was
discussed. The guidelines can be downloaded from
the Internet. They broadly cover acute cholecystitis
and cholangitis. It stresses early laparoscopic chole-
cystectomy for acute cholecystitis and endoscopic
drainage for cholangitis.
A debate on the neoplasms of gallbladder discussed
open or laparoscopic approach. Laparoscopic chole-
cystectomy was preferred unless frozen section
showed invasive carcinoma when conversion to open
procedure was mandatory.
On March 1st, a symposium on carcinoma Gall-
bladder was held. First, Prof. Anil Agarwal stressed
that for T1a  Cholecystectomy alone is sufficient. For
T1b, radical cholecystectomy needs to be done. In a
postoperative patient with histopathology of carci-
noma gallbladder, early resection is to be done.
Involvement of Rokitansky  Aschoff sinus has a
poor outcome in Prof. Aretxabala’s view. If this is
seen then radical surgery is needed. Prof. Kondo
showed that presence of para-aortic lymphadenopathy
is metastatic disease. Any positive lymph nodes show
poor prognosis and the best chance of survival is R0
resection. Adjuvant treatment of carcinoma gall
bladder is shown to be ineffective at present and
needs to be further evaluated.
A debate on whether bile duct resection should be
routine for carcinoma gallbladder had Prof. Miyazaki
state that this helps in better tumour clearance and
lymphadenectomy. However, Prof. Sadiq Sikora did
not support the concept that routine bile duct excision
leads to better survival or lymphadenectomy.
Prof. Nimura, in his keynote address in ‘Lessons
learnt in management of Biliary malignancies’
stressed on MDCT before stenting. Routine Percuta-
neous Transhepatic Biliary Drainage (PTBD) and
Portal vein Embolisation (PVE) improved results.
Extended resection with vascular reconstruction and
neo-adjuvant chemoradiation improved results.
Prof. Gouma discussed the management of com-
plex bile duct injury. He stressed on a multidisciplin-
ary approach and that stenting was useful in 20% of
patients. Acute repair, higher injury and intervention
had poor results. Drainage does not affect results.
Short term (B6 months) stenting does not affect
outcome of operation.
Dr. Strasberg in his talk on ‘Exercising safety in
Biliary Surgery’ stressed on the ‘error traps’ in
cholecystectomy. He showed that in conversion of
laparoscopic to open cholecystectomy ‘fundus down’
led to some major vascular or biliary injury.
The Ganga study, an epidemiological study was
presented. It assessed the prevalence of carcinoma
gallbladder and stone disease. It seemed to implicate
heavy metals in gallbladder cancer.
Prof. VK Kapoor talked on evidence-based medi-
cine in biliary tract. He felt that endo biliary metal
stents should be used in malignancy if life expectancy
is B6 months. Surgery is better for patients who
expected to live longer. Metal stents are to be avoided
in benign strictures. In India, early carcinoma gall-
bladder should be treated aggressively with palliation
for advanced tumours.
On 2nd March, a symposium on Intrahepatic
Cholangiocarcinoma (ICC) was conducted. Three
main types of ICC are identified  Mass, periductal
and intraductal, with mass being the predominant
type. Mass alone has a better prognosis. Positive
lymph nodes, intrahepatic metastasis, grading, pre-
sence of jaundice and raised CA19-9 have poor
prognosis.
ICC has hepatolithiasis as a risk factor. Western and
Eastern experiences are similar. Extended R0 resec-
tion for single and lymph node negative tumours have
better survival. Overall, 24% five-year survival was
reported.
Lastly, a session of CBD stones was conducted.
The conclusion was that available expertise makes the
choice. Both endoscopic and laparoscopic approaches
are effective. Small ducts should be tackled endosco-
pically. LCBDE offers advantage of one stage proce-
dure and intact ampulla.
Ramesh Ardhanari
Madurai
India
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Pancreas summary  IHPBA 2008
The 8th World Congress of the IHPBA in Mumbai
was a fantastic event for the HPB community. Over
500 abstracts focused on multiple aspects of pancrea-
tic diseases including acute and chronic pancreatitis,
pancreatic tumors, as well as pancreatic trauma and
transplantation were presented as keynote lectures,
video sessions, symposia, oral and poster presenta-
tions. Thus, in this summary I can only focus on some
of the highlights presented.
Over the past years it became evident, that the
surgeon and high-volume hospitals are main factors
for the outcome for pancreatic surgery (Strasberg and
Bassi, SY15). Sethi et al. from London, UK (PP
31.06) and Mittal et al. from Soutfield, USA (FP
17.02) could demonstrate that specialization of phy-
sicians and centralization of the treatment of hepato-
pancreato-biliary diseases exert positive effects on
resection rate, morbidity and mortality, as well as on
costs at their institutions. In addition, data from
Newcastle upon Tyne, UK (PP.05.02) proofed for
the first time in an observational study of 18 hospitals
that caseload also affects mortality in the treatment of
acute pancreatitis.
Acute pancreatitis  Early prediction of severity of
the disease is one of the main issues in the manage-
ment of acute pancreatitis. An artificial neural net-
work which applies data from a large population to an
individual and identifies patterns within data that are
associated with a particular outcome was proven to be
superior to conventional scoring systems (R. Parks,
SY 7.01). Increased D-dimer levels seem to predict
the development of organ failure already on admission
(AP2.04). However, the routine applicability of
these new predictors needs to be validated. Today,
prevention of infection during the course of pancrea-
titis is the main treatment goal. So far, no treatment
agent has successfully decreased either infection rate
or mortality. In fact, a recent randomized multicenter
trial showed that probiotics increase mortality and
should not be used in acute pancreatitis. Thus,
supportive intensive care is the only treatment that
can be advocated in severe pancreatitis (J. Werner, SY
7.01).
Chronic pancreatitis  Tropical pancreatitis is a
special form of chronic pancreatitis which is not
observed in the Western world. In India, the disease
pattern has changed over the last 30 years due to
change of lifestyle, nutrition, and alcohol consump-
tion. Most patients today present with a mixture of
alcoholic and tropical form of pancreatitis (UL 8.01).
Mihir et al. (PP 28.10) demonstrated that the
combination of pancreatic head resections and surgi-
cal drainage result in an excellent pain relief in over
95% of all patients. These results support the latest
randomized controlled trial which showed that surgi-
cal drainage is superior to endoscopic drainage in
patients with pancreatic duct stenosis. Two other
presentations (Vashist et al. FP 15.03, Van der Gaag
et al. FP 15.06) demonstrated that reoperations in
patients with chronic pancreatitis are needed in 5
15%, most frequently for recurrent pain. The Ham-
burg group could show that most of the time a
duodenum-preserving pancreatic head resection can
successfully be performed even as a redo-resection.
These reports underline the important role of surgical
treatment in chronic pancreatitis today.
Pancreatic tumors  Radical surgical approaches for
pancreatic cancer have been reported for advanced
pancreatic tumors. To achieve free resection margins
the early dissection of the superior mesenteric artery
has been advocated by two groups as the ‘‘artery first
approach’’ (Bu¨chler, Heidelberg, Germany) or the
‘‘hanging maneuver’’ (Jaeck, Strasbourg, France).
While venous resection is a well-accepted standard
in case of infiltration in pancreatic cancer, arterial
resection is rarely reported. Two abstracts from Japan
(Miyazaki et al. FV 1.01; Hirano et al. FV 6.05)
reported on distal pancreatectomy with en bloc
resection of the celiac trunk with a median survival
of 21 months in 23 patients. The resection of the
hepatic artery is also technically feasible, but median
survival was only 10 months (Hoshino et al. FV 1.04,
Jaeck et al. PP 17.10). Today, many rare pancreatic
tumors are identified more frequently secondary to
the frequent usage and technical advances of imaging
techniques. Alone seven abstracts reported about
solid pseudopapillary neoplasms (Frantz tumors) so
that we can expect a lot of interesting results on the
pathologies of these rare tumors in the near future.
Surgical techniques  Minimal invasive surgical
techniques have been advocated for almost any
pancreatic disease and procedure. Twenty-three
presentations reported that laparoscopic approaches
are safe and feasible in experienced hands. However,
no randomized controlled study has been published
so far. An exception is the multicenter PANTER trial
of the Dutch Acute Pancreatitis Study Group which
compares conventional open necrosectomy with a
minimal invasive step-up approach in necrotizing
pancreatitis which will close recruitement soon.
The pancreatic anastomosis is the most demanding
one in pancreatic surgery. Peng et al. demonstrated a
leakage rate of 0.5% with a simple binding technique
in over 300 cases (SY4.03). However, reports from
other institutions on the safety of this technique from
Hong Kong (FP 32.05) and India (PP 63.10) with
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fistula rates of 53% (11/21) and 7.5% (1/15) demon-
strate that caseload is a key factor in pancreatic
surgery and that standardized definitions of complica-
tions need to be used for comparisons of results
between institutions. Internationally accepted and
standardized definitions of pancreatic complications
including fistula have been published recently. The
ISGPF definition of pancreatic fistula was used in
nine studies presented at this meeting demonstrating
the importance of such standardizations.
Jens Werner
University of Heidelberg
Germany
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